Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Year In Review: Biotech Industry Not As Optimistic About Financing As Analyst Community

Executive Summary

After a bleak 2009, it is not difficult to find market analysts who anticipate a much brighter picture for biotech finance in the new year - but those sentiments are not always echoed by the people on the ground. Venture capitalists and high-ranking biotech executives still see a world of tight money and dubious exit potential for investors with continued reliance on merger and acquisition activity for the near-term

You may also be interested in...

Financings Of The Fortnight: Movetis Files First European Biopharma IPO Since Early 2008

Notable biotech financings in November also include ThromboGenics, NicOx: 4SC AG, and Fate Therapeutics.

Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder

The deal also requires Bristol to make an equity investment of up to $20 million should Alder go public.

Dealmaking When Pharma's the Only Game in Town

With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts